simplified the treatment improves the adhesion and facilitates compliance.
The World Health Organization (WHO) estimates that adherence to long-term treatments in industrialized countries reaches only 50 percent of patients, and that adherence is even lower in developing countries developing. A lot of patients find difficulty in complying with treatment, and while many reasons have been cited for this lack of adhesion, one of the main predictors of compliance is the number of times per day the patient should take medication. Several studies suggest that simplify the treatment regimen improves adherence and facilitates compliance.
chronic conditions such as osteoarthritis (OA), rheumatoid arthritis or some sports injuries that require the use of long-term analgesics for the treatment of pain, and patients who receive pain medication regularly, mainly over 65 years and those with one risk factor, may experience symptoms such as nausea, heartburn, indigestion or pain in the stomach. Various international medical societies recommend that patients who require continuous administration of NSAIDs (NSAIDs) perform a simultaneous treatment with agents that inhibit the secretion of stomach acid as inhibitors called proton pump inhibitors (PPIs) including omeprazole.
is available in Argentina
is medicine in a single capsule contains an anti-inflammatory and proton pump inhibitors.
is a multinational development Bagó Argentina, and the only one in the world that combines innovative technology, in the same capsule, diclofenac and omeprazole. "The association of both drugs in a housing offers advantage of a smaller number of samples to be performed because the patient is generally polymedicated "said Dr. Augusto Riopedre, Argerich Hospital rheumatologist doctor and vice president of the Association of Rheumatology of the City of Buenos Aires. The combination of both drugs in one capsule simplifies decision for the patient and avoid oversights or errors in dosage, which is an advantage for greater adherence to treatment. "While the simultaneous administration of omeprazole with an NSAID reduces the risk of gastrointestinal complications, adherence of patients taking two drugs separately is suboptimal. This new combination of drugs can improve adherence and thereby achieve a more effective way to reduce the risk of complications, "said Dr. Soifer . "The advantage for adhesion is the declining number of outlets of medicines and reducing the possibility of forgetting the same schedule mainly by elderly patients," added Riopedre.
For his part, Dr. Arnoldo Albero, founder and former president of the Argentina Society of Sports Traumatology and director of the Medical Department of Women's Volleyball Team of Argentina stressed that the association of diclofenac and omeprazole a single capsule is also an option for young athletes for whom gastric protection is essential as they are subjected to stressful activities that require high physical demand. "It also allows to extend the indications of chronic inflammatory diclofenac in any patient with gastrointestinal and medicating lability elderly patients are more likely to develop gastrointestinal lesions." added.
The NSAID diclofenac is the number one and eighth best-selling drug worldwide. It is the most common analgesic used to treat pain, especially in those cases in which inflammation is the cause of it. Among its many uses, including rheumatic diseases, tendonitis, bursitis, sciatica, myalgia, headaches, sprains and strains, as well as postoperative pain, dental or gynecological conditions associated with, among others. Omeprazole is the world's most widely used drug in the treatment and prevention of gastric and duodenal ulcer disease.
- An innovative Argentine development
The new combination of drugs diclofenac and omeprazole in a single capsule, which combines technology innovatively multiparticulate systems, is a development of Laboratories Bago, Argentina a multinational presence in over 45 countries worldwide. "This product combination of two assets, is an innovative response to a therapeutic niche that does not have similar or the country or the world. Combine them into a single capsule has the important advantage that the physician may have a better monitoring of treatment efficacy and compliance with the dosing schedule, "said Dr. Luis Dall, Chemical Development by Bago Special Products.
combine to achieve both active in a single product, it was necessary to avoid different pharmaceutical and technical challenges. "The first consideration to take into account was that both active systems should be formulated as delayed release (enteric) and follow the latest market trends and from the standpoint of innovation, this system should be multiparticulates. We use two systems and enteric multiparticulates of whom were experienced: diclofenac sodium enteric enteric multiparticulates and omeprazole sodium multiparticulates " described Dall. In multiparticulate technology (multiple units totaling dose) the drug is released through small and multiple microspheres, in which each functions as a unit, allowing a more regular release and absorption of the drug during transit gastro-intestinal and less influence of the presence of food. This means a clear advantage compared to classical biopharmaceutical enteric coated tablet or capsule including enteric soft. Studies have shown that enteric multiparticulate system, compared with classic enteric tablet, provides more rapid absorption and regular assets, allowing, for its small size, one step at Agile gastric and intestinal.
In recent years, Laboratorios Bago set as one of its objectives, developing new formulations, even conventional drugs or molecules, in order to facilitate patient adherence to treatment and in some cases improve the properties of the active ingredient. "There is always a need to improve the administration of drugs whose effectiveness has been widely proven but which have some difficulties in either administration or assimilation. While there are some developments in the world that combine anti-inflammatory inhibitors, proton pump, the particular combination of diclofenac and omeprazole has not so far in the background world. " said Dr. Eduardo de la Puente, Medical Director of Laboratories Bago. "Bago In this development offers for the patient not only an advantage in taking the medication but also an economic benefit, since the cost of combination therapy with both drugs alone is greater than the product in combination," concluded the the Bridge.
- Seniors poly
People over 65 account for 10 to 25 percent of the population and consume 25 to 50 percent of prescribed drugs. It is estimated that 36 percent of older adults have more than 3 chronic diseases, which is usually translated in a "polypharmacy" it can be difficult to manage. Most of these patients are susceptible to errors and problems associated with taking drugs. The study "Medication errors and lack of adherence in the elderly", revealed that one of the main factors related to medication errors and nonadherence in patients over 65 years is the number of drugs prescribed.
For WHO, adherence to treatment in the elderly requires special attention. Although anyone at any age can remember to take medication in some patients over the memory difficulties may be exacerbated. Many older adults simultaneously receiving multiple medications for the treatment of various chronic conditions, resulting in a regimen that requires taking multiple drugs throughout the day.
0 comments:
Post a Comment